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Editorial on the Research Topic
P2X7 as Common Therapeutic Target in Brain Diseases
Despite differences in disease etiology (e.g., β-amyloid, polyglutamine expansion, or
neurodevelopmental abnormalities), several brain diseases (e.g., Alzheimer’s disease, epilepsy,
or schizophrenia) share common clinical symptoms with overlapping diagnoses including
depression, psychotic episodes, cognitive deficits, anxiety, and seizures. This implies the activation
of shared pathological pathways in different brain diseases. An emerging concept is that increased
hyperexcitability and network changes are universal pathomechanisms in numerous brain diseases
(Palop and Mucke, 2010; Cepeda-Prado et al., 2012; Kanner, 2012; Nakahara et al., 2018). As well
as neurons, glial cells are involved in network hyperexcitability and the mediation of inflammatory
processes by modulating the release of neurotransmitters and pro-inflammatory cytokines (Robel
and Sontheimer, 2016).
Purinergic signaling mediated via specific purinergic membrane receptors, which are activated
by extracellularly released nucleosides (P1 adenosine receptors) and nucleotides [e.g., adenosine
triphosphate (ATP)] (P2Y and P2X receptors), were suggested to play an important role in
numerous human pathological conditions including diseases of the central nervous system (CNS)
(Burnstock, 2020). The P2X7 receptor belongs to the ATP-gated ionotropic P2X receptor family.
Among the P2X receptors, it has some unique structural and functional characteristics, that make
this receptor a particularly attractive therapeutic target (Sperlagh and Illes, 2014; Jimenez-Mateos
et al., 2019; Kopp et al., 2019). In particular, it has a much lower affinity for ATP [activation
threshold: 0.3–0.5mM; however, decreased activation threshold (0.05–0.1mM) has been reported
during inflammation (Di Virgilio et al., 2017)], suggesting that its activation occurs mainly under
pathological conditions of high ATP release. Furthermore, it is slowly desensitizing, can induce
plasma membrane permeabilization for large molecules, and is a key driver of inflammation
(Di Virgilio et al., 2017). Studies have attributed a wide array of pathological processes to P2X7
receptor activation in the brain, most prominently the activation of pro-inflammatory processes
and regulation of neurotransmitter release. In addition, P2X7 activation has been linked to other
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FIGURE 1 | P2X7 receptor activation as shared pathological pathway in brain diseases. Usually found at low extracellular concentrations, ATP levels strongly increase
during noxious conditions in the brain. Once released, ATP activates specific purinergic receptors including the ionotropic P2X7 receptor which, in turn, contribute to
multiple pathological processes shared among several neurological and psychiatric brain diseases including neuroinflammation, increased hyperexcitability, and
neurodegeneration thereby driving disease progression.
damaging processes such as the promotion of cell death,
hyperexcitability, and permeabilization of the blood brain barrier
(Sperlagh and Illes, 2014). These are shared by the majority
of brain diseases and potentially contribute to both primary
disease pathology and associated comorbidities (Figure 1).
In support of this hypothesis, mounting data demonstrate
beneficial effects of P2X7 receptor antagonism in numerous
brain diseases including neurodegenerative, psychiatric, and
neurological diseases (Sperlagh and Illes, 2014).
This Research Topic comprises 11 articles containing five
reviews, three original research articles, two brief research reports
and one hypothesis/theory article that summarize P2X7 receptor
research in different brain diseases and provide up-to date
and focused insights into the role of the P2X7 receptor and
its potential as a drug target. In the review article written by
Francistiová et al. novel findings of the role the P2X7 receptor in
Alzheimer’s disease are highlighted including data from animal
models and humans. Ruiz-Ruiz et al. provided a review about the
role of the P2X7 receptor in amyotrophic lateral sclerosis with
a particular focus on how the mitigation of neuroinflammation
via P2X7 receptor blockade may lead to a higher motoneuron
survival in patients. Cisneros-Mejorado et al. reviewed the latest
findings on the P2X7 receptor in cerebro-vascular disease and
Illes et al. contributed an up-to date summary of the P2X7
receptor involvement in major depression and bipolar disorders
focussing on possible contributions from both astrocytes and
microglia. Finally, Andrejew et al. discusses the molecular
mechanisms underlying P2X7 receptor-mediated signaling in
neurodegenerative diseases, psychiatric disorders, and brain
tumors and highlights the recent advances in the development
of P2X7 receptor antagonists. The original research article by
Ollà et al. shows for the first time increased P2X7 receptor
protein levels in the brain of patients with Huntington’s disease
supporting the idea that the P2X7 receptor provides a possible
therapeutic target in this devastating disease. Interestingly, the
observed increases in P2X7 receptor expression in patients are
accompanied by disease-specific alterations in the expression of
different P2X7 receptor splice variants. Using a mouse model
of intraperitoneal phencyclidine (PCP), Calovi et al. support
the idea of the P2X7 receptor as a potential therapeutic target
in schizophrenia. Using mouse models with either increased or
decreased P2X7 receptor expression, the authors show that the
P2X7 receptor drives PCP-mediated effects including changes in
behavior, basal dopamine concentrations, layer-specific neuronal
activation, intrinsic excitability of neurons and the interaction
of microglia with hyperactive neurons. In a mouse model of
status epilepticus, Conte et al. show for the first time how
P2X7 receptor signaling impacts on the expression profile of
microRNAs in the brain during normal physiology and following
prolonged damaging seizures (i.e., status epilepticus) and suggest
a novel pathway of how the P2X7 receptor might contribute
to the gene expression landscape during both the maintenance
of normal cellular homeostasis and pathological processes. In
one of the brief research reports Bibič and Stokes tested the
hypothesis of the P2X7 receptor being activated via amyloid
β peptides. Performing different in vitro studies, the authors
found, however, no evidence that amyloid β peptides act as
agonists of the P2X7 receptor and conclude that amyloid β
peptides simply mimic features of P2X7 receptor activation.
In another brief research article, Rissiek et al. evaluated the
susceptibility of astrocytes andmicroglia to cell death induced via
P2X7 receptor activation through its ADP-ribosylation caused by
NAD+. Their data show that treatment of microglia or astrocytes
with NAD+ resulted neither in the activation of the P2X7
receptor nor induction of cell death and explain these results with
the finding that astrocytes and microglia preferentially express
the ADP-ribosylation-insensitive P2X7a splice variant. Finally,
Sanz et al. found a correlation of certain P2X7 receptor single
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nucleotide polymorphisms (SNPs) with age and hypothesize
that these SNPs may promote an anti-inflammatory phenotype,
thereby extending life expectancy among the European and
North-American Caucasian population.
In summary, this Research Topic provides a state of-the
art description of P2X7 receptor research in the CNS, further
supporting the concept of P2X7 activation being a shared
pathological pathway among a broad spectrum of brain diseases.
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